Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphoma
NCT06513234Phase 2Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in marginal zone lymphoma (MZL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete Response Rate at 12 months. Started Jul 2024; status: active, not recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06513234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513234.